ArticleDiagnostics (Basel, Switzerland)2023
Comparison of the Effects of DOTA and NOTA Chelators on
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Influences of Ring Sizes and Chiral Substituents on Macrocyclic Chelators for ImprovingJACS Au · 2026Article
- Article
- Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.EJNMMI research · 2025Review
- Side by side comparison of NOTA and DOTA for conjugation efficiency, gallium-68 labeling, and in vivo biodistribution of anti-mesothelin sdAb A1-His.EJNMMI radiopharmacy and chemistry · 2025Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Is Copper-61 the New Gallium-68? Automation and Preclinical Proof-of-Concept ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.Molecules (Basel, Switzerland) · 2025Article
- Article
- Editorial for Special Topics: Imaging-Based Diagnosis for Prostate Cancer-State of the Art.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study compared the effects of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) as
methodsThe in vitro stability of the chelators was evaluated using human and mouse serum. In vitro PSMA-binding affinity and cell uptake were compared using human 22Rv1 cells. To evaluate specific PSMA-expressing tumor-targeting efficiency, micro-positron emission tomography (mcroPET)/computed tomography (CT) and biodistribution analysis were performed using PSMA+ PC3-PIP and PSMA- PC3-flu tumor xenografts.
resultsThe serum stability of DOTA- or NOTA-conjugated
conclusionsThis study indicates that the PSMA-targeted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.